Indirect Health Care Costs

The quantifiable costs associated with human disease and illness are typically categorized into two unique components, including direct and indirect costs. Direct costs usually represent the costs associated with medical resource utilization, which include the consumption of in-patient, out-patient, and pharmaceutical services within the health care delivery system. The term indirect costs has come to be defined as the expenses incurred from the cessation or reduction of work productivity as a result of the morbidity and mortality associated with a given disease. Indirect costs typically consist of work loss, worker replacement, and reduced productivity from illness and disease. These losses are typically valued from either societal, individual, or employer perspectives (1,2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic €32.70 /Month

Buy Now

Price includes VAT (France)

eBook EUR 93.08 Price includes VAT (France)

Softcover Book EUR 116.04 Price includes VAT (France)

Hardcover Book EUR 158.24 Price includes VAT (France)

Tax calculation will be finalised at checkout

Purchases are for personal use only

Preview

References

  1. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60: 429–462. ArticlePubMedCASGoogle Scholar
  2. Eisenberg JM. Clinical Economics- A guide to the economic analysis of clinical practices. JAMA 1989; 262: 2879–2886. ArticlePubMedCASGoogle Scholar
  3. Herrin J, Cangialose CB, Boccuzzi SJ, et al. Household income losses associated with ischaemic heart disease for US employees. Pharmacoeconomics 2000; 3: 305–314. Google Scholar
  4. Koopmanschap MA, Rutten FF. Indirect costs in economic studies: confronting the confusion. Pharmacroeconomics 1993; 4: 446–454. ArticleCASGoogle Scholar
  5. American Heart Association. 2001 Heart and Stroke Statistical Update. American Heart Association, Dallas, TX, 2000. Google Scholar
  6. Burton WN, Conti DJ, Chen CY, et al. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J Occup Environ Med 2002; 44: 523–529. ArticlePubMedCASGoogle Scholar
  7. Bartell A, Taubman P. Health and labor market success: the role of various diseases. Rev Econ Stat 1979; 61: 1–8. ArticleGoogle Scholar
  8. Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. Int J Technol Assess Health Care 1998; 14: 799–808. ArticlePubMedCASGoogle Scholar
  9. Drummond M. Cost-of-illness, a major headache? Pharmacoeconomics 2992; 2: 1–4. ArticleGoogle Scholar
  10. Weinstein MC, Siegel JE, Garber AM, et al. Productivity costs, time costs and health related quality of life: a response to the Erasmus Group. Health Econ 1997; 6: 505–510. ArticlePubMedCASGoogle Scholar
  11. Berger ML, Murray JF, Xu J, Pauly M. Alternative valuations of work loss and productivity. J Occup Environ Med 2001; 43: 18–24. ArticlePubMedCASGoogle Scholar
  12. Berdt ER, Finklestein SN, Greenberg PE, et al. Workplace performance effects from chronic depression and its treatment. J Health Econ 1998; 17: 511–535. ArticleGoogle Scholar
  13. Burton WN, Conti DJ, Chen CY, et al. The role of health risk factors and disease on worker productivity. J Occup Environ Med 1999; 41: 863–877. ArticlePubMedCASGoogle Scholar
  14. Goetzel RZ, Guindon AM, Turshen IJ, Ozminkowski RJ. Health and productivity management: establishing key performance measures, benchmarks and best practices. J Occup Environ Med 2001; 43: 10–17. ArticlePubMedCASGoogle Scholar
  15. Stern S. Measuring the effect of disability on labor force participation. J Human Resources 1989; 24: 360–394. ArticleGoogle Scholar
  16. Hodgson TA. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics 1994; 6: 536–552. ArticlePubMedCASGoogle Scholar
  17. Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. Int J Technol Assess Health Care 1998; 14: 799–808. ArticlePubMedCASGoogle Scholar
  18. Rizzo JA, Abbott TA, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996; 5: 249–265. ArticlePubMedCASGoogle Scholar
  19. Rice DP. Estimating the cost of illness. Am J Public Health 1967; 57: 424–440. ArticleCASGoogle Scholar
  20. Cooper B, Rice DP. The economic cost of illness revisited. Soc Sec Bull 1976; 39: 21–36. CASGoogle Scholar
  21. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoenoomics 1998; 13: 1–7. ArticleCASGoogle Scholar
  22. Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity cost measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997; 6: 253–259. ArticlePubMedCASGoogle Scholar
  23. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–189. ArticlePubMedCASGoogle Scholar
  24. Koopmanschap MA, van Ineveld BM. Toward a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005–1010. ArticlePubMedCASGoogle Scholar
  25. Koopmanschap MA, Rutten FFH. The impact of indirect costs on outcomes of health care programs. Health Econ 1994; 3: 385–393. ArticlePubMedCASGoogle Scholar
  26. Koopmanschap MA, Rutten FFH. The consequence of production loss or increased costs of production. Med Care 1996; 34: 12. ArticleGoogle Scholar
  27. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460–466. ArticlePubMedCASGoogle Scholar
  28. Correspondance. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13: 563–569. Google Scholar
  29. Johannesson M, Karlsson G. The friction cost method: a comment. J Health Econ 1997; 16: 249–255. ArticlePubMedCASGoogle Scholar
  30. Guico-Pabia CJ, Murray JF, Teutsch SM, et al. Indirect costs of ischemic heart disease to employers. Am J Manag Care 2001; 7: 27–34. PubMedCASGoogle Scholar
  31. Sagmeister M, Gessner U, Horisberger B, Gutzwiller F. An economic analysis of ischaemic heart disease in Switzerland. Eur Heart J 1997; 18: 1102–1109. ArticlePubMedCASGoogle Scholar
  32. Pestana JAX, Steyn K, Leiman A, Hartzenberg GM. The direct and indirect costs of cardiovascular disease in South Africa in 1991. S A Med J 1996; 86: 679–684. Google Scholar
  33. Zethraeus N, Molin T, Henriksson P, Jonsson B. Costs of coronary heart disease and stoke: the case of Sweden. J Intern Med 1999; 246: 151–159. ArticlePubMedCASGoogle Scholar
  34. Evans CJ, Crawford B. Data collection methods in prospective economic evaluation: how accurate are the results. Value in Health 2000; 3: 277–286. ArticlePubMedCASGoogle Scholar
  35. Greenberg PE, Birnbaum HG, Kessler RC, et al. Impact of illness and its treatment on workplace costs: regulatory and measurement issues. J Occup Environ Med 2001; 43: 56–63. ArticlePubMedCASGoogle Scholar
  36. Canadian Coordinating Office for Health Technology assessment. A Guidance Document for the Costing Process. Canadian Coordinating Office for Technology Assessment, Ottawa, Canada, 1996. Google Scholar
  37. Canadian Coordinating Office for Health Technology assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada, 2nd ed. Canadian Coordinating Office for Technology Assessment, Ottawa, Canada, 1997. Google Scholar
  38. Commonwealth Department of Human Services and Health, Australia. Australian Guidelines. Australian Government Publishing Service, Canberra, Australia, 1995. Google Scholar
  39. Riteco JA, Heij LJ, Luijn JC, et al. Richtlijnen Voor farmaco-economisch onderzoek. Amstelveen: College voor zorgverzekeringen, 1999. Google Scholar
  40. Siegel JE, Torrance GW, Russel LB, et al. and the Members on the Panel of Cost Effectiveness in Health and Medicine. Pharamcoeconomics 1997; 11: 159–168. ArticleCASGoogle Scholar
  41. Botman SL, Jack SS. Combining National Health Interview survey datasets: issues and approaches. Statistics in Med 1995; 14: 669–677. ArticleCASGoogle Scholar
  42. National Death Index, Division of Vital Statistics, National Center for Health Statistics. (http://www.cdc.gov) accessed 2002, Hyattsville, MD.
  43. United States Bureau of Labor Statistics. (http://www.bls.gov) accessed 2002, Washington, DC.
  44. United States Department of Commerce. (http://www.commerce.gov) accessed 2002, Washington, DC.
  1. Stephen J. Boccuzzi PhD, FAHA
You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA William S. Weintraub MD

Rights and permissions

Copyright information

© 2003 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Boccuzzi, S.J. (2003). Indirect Health Care Costs. In: Weintraub, W.S. (eds) Cardiovascular Health Care Economics. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-398-9_5

Download citation

Share this chapter

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative